Genetics market size surges amid sequencing boom and therapy wins
The global genetics economy is accelerating as cheaper sequencing, expanding clinical testing, and landmark gene therapy approvals unlock new demand. Investors are eyeing double-digit growth through the decade, with leaders in instruments, consumables, and services competing for share.
The big picture: a rapidly scaling genetics economy
In the Genetics sector, The genetics market—spanning genomics tools, next‑generation sequencing (NGS), clinical genetic testing, and gene therapies—has entered a faster growth phase as research applications spill into clinical care. On the tools side, the global genomics segment was valued at roughly the low‑$30 billions in 2023 and is poised to more than double by 2030, according to industry reports. That trajectory reflects not only new instrument placements but, more importantly, a rising base of recurring consumables and informatics revenue.
Within clinical services, payers and health systems are integrating hereditary cancer, carrier, and pharmacogenomic testing into care pathways, creating durable demand. Meanwhile, the therapeutics segment—still smaller today—adds a long runway as gene therapy moves beyond rare disease pilots into mainstream indications. Together, these segments suggest a maturing market with multiple, diversified growth engines.
For investors and operators, the implication is clear: genetics is transitioning from a research‑centric niche to a healthcare platform. As data volumes compound and clinical utility strengthens, revenue visibility improves—particularly for companies positioned at the junction of hardware, chemistry, and software.
Segment dynamics: testing, sequencing, and gene therapy
Genetic testing is the most visible clinical wedge, supported by broader reimbursement and provider adoption. The global genetic testing market reached the high‑teens billions in 2023 and is projected to approach $30 billion by 2028, industry reports show. Growth is led by oncology (hereditary risk, tumor profiling and minimal residual disease), prenatal and carrier screening, and a re‑emerging interest in pharmacogenomics as payers refine coverage policies.
NGS—anchored by installed platforms from Illumina, Thermo Fisher Scientific, Roche, Qiagen, and BGI—continues to expand through lower run costs, higher throughput, and improved bioinformatics. While instrument revenue can be cyclical, the consumables model remains resilient as labs increase utilization. The NGS market has been hovering around low‑double‑digit billions, with the installed base and workflow automation suggesting sustained mid‑teens growth in clinical and translational use cases.
...